

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Bridgelall, et al.

Examiner: Kimberly D. Nguyen

Serial No.:

09/819,970

Group: Art Unit 2876

Filed:

March 27, 2001

Docket: 1400-7 (1128)

Dated: December 23, 2002

For:

COMPACT AUTO ID READER AND RADIO FREQUENCY

TRANSCEIVER DATA COLLECTION MODULE

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to Applicant(s) duty of disclosure, the information sted in the attached form PTO-1449 is brought to the attention of the Examiner. Copies of the listed items are enclosed.

The citation of the listed items is not a representation that they constitute a complete or exhaustive listing of the relevant art or that the references are prior art.

The items listed are submitted in good faith, but are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner of these particular items, they will assist in identifying fields of search and in making as full and complete a search as possible.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to the: Assistant Commissioner for Patent Washington, D.C. 20231 on December 23, 2002.

Dated: December 23, 2002

Adrienne Fagan

01/02/2003 HBLANCO 00060032

01 FC:1806

The PTO did not receive the following 80,00 listed Items(s) A Check OF 9

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as 37 C.F.R. § 1.56(b).

- This information disclosure statement is being filed within three (3) [] months of the filing date of this application. This information disclosure statement is being filed within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. To the best of Applicant(s) knowledge, this supplemental information disclosure statement is being filed before the date of mailing of a first Office Action on the merits in connection with this case. []Enclosed herewith is a certificate under 37 C.F.R. § 1.97(e)(1). [] Enclosed herewith is a petition under 37 C.F.R. § 1.97(d)(ii). Enclosed by check is the petition fee of \$130.00. (37 C.F.R. §1.17(i)(1)) Please charge the \$130.00 petition fee to Deposit Account No. 50-2140.
- [X] Enclosed by check is the \$180.00 fee required by 37 C.F.R. § 1.17(p).
- [] Please charge the \$180.00 fee required by 37 C.F.R. §1.17(p) to Deposit Account No. **50-2140**.
- [X] Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R §1.16 and/or §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 50-2140. Also, in the event any extensions of time for responding and/or a petition under 37 C.F.R. §1.17(i)(i) are required for the pending application(s), please treat this paper as a petition to extend the time and/or enter this Supplemental Information Disclosure Statement as required and charge Deposit Account No. 50-2140 therefor. TWO (2) COPIES OF THIS SHEET ARE ENCLOSED.

The claims of the application as now presented are believed to be patentably distinguish over the prior art and to be in condition for allowance. Early and favorable consideration of this application are respectfully requested.

Respectfully submitted,

George Likourezos

Reg. No. 40,067

Attorney for Applicant(s)

CARTER, DELUCA, FARRELL & SCHMIDT, LLP 445 Broad Hollow Road Suite 225 Melville, New York 11747

Phone: (631) 501-5700 Fax: (631) 501-5715

GL/cs/af

ORMATION DISCLOSURE CITATION IN AN APPLICATION

Use several sheets if necessary)

Docket Number (Optional) 1400-7 (1128) Application Number 09/819,970

Applicant

RAJ BRIDGELALL et al.

Filing Date 3/27/01

Group Art Number 2876

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
KN	5,449,893	9/12/95	Bridgelall et al.	0.000		
	5,478,997	12/26/95	Bridgelall et al.			
		4/2/96	Bridgelall et al.			
	5,504,316	4/2/96	Marom et al.	+		
	5,504,595			 		
	5,525,788	6/11/96	Bridgelall et al.			
	5,545,888	8/13/96	Barkan et al.			
	5,555,130	9/10/96	Marom et al.			
	5,569,901	10/29/96	Bridgelall et al.		-	
	5,581,072	12/3/96	Bridgelall et al.			
	5,600,121	2/4/97	Kahn et al.	-		
	5,608,202	3/4/97	Bridgelall et al.			ļ
	5,637,856	6/10/97	Bridelall et al.	ļ		
	5,648,649	7/15/97	Bridgelall et al.	ļ		
	5,691,528	11/25/97	Wyatt et al.			
	5,767,500	6/16/98	Cordes et al.			
	5,793,032	8/11/98	Bard et al.			
	5,801,371	9/1/98	Kahn et al.			
	5,821,521	10/13/98	Bridgelall et al.			
	5,859,417	1/12/99	Dvorkis et al.			
	5,861,615	1/19/99	Bridgelall et al.			
	5,889,269	3/30/99	Bridgelall et al.			
	5,907,146	5/25/99	Bridgelall et al.			
	5,914,478	6/22/99	Bridgelall et al.			
V	5,925,872	7/20/99	Wyatt et al.			
RN	5,955,720	9/21/99	He et al.	1		

OTHER DOCUMENTS

_	•	
HVa	min	or

KinMMuyan

Date Considered

3/17/63

Examiner: Imital if citation considered, whether or nor citation is in conformance with MPEP §609; Draw line through

citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Form PTO-1449 RMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional) 1400-7 (1128)

Application Number 09/819,970

Applicant

RAJ BRIDGELALL, et al.

Filing Date 3/27/01 Group Art Number 2876

Document Number Date Name Class Subclass Filing Initial	U.S. PATENT DOCUMENTS								
6,029,893 2/29/00 Tan et al. 6,092,725 7/25/00 Swartz et al. 6,095,418 8/1/00 Swartz et al. 6,095,421 8/1/00 Barkan et al. 6,101,483 8/8/00 Petrovich et al. 6,114,712 9/5/00 Dvorkis et al. 6,164,540 12/26/00 Bridgelall et al. 6,170,749B1 1/9/01 Goren et al. 6,209,788B1 4/3/01 Bridgelall et al. 6,220,514B1 4/24/01 Dvorkis et al. 6,264,106B1 7/24/01 Bridgelall et al. 6,330,973B1 12/18/01 Bridgelall et al. 6,334,573B1 1/1/02 Li et al. 6,360,949B1 3/26/02 Shepard et al. 6,3405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,410,931B1 6/25/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al.	1 1		Date	Name	Class	Subclass	Filing Date if Appropriate		
6,029,893 2/29/00 Tan et al. 6,092,725 7/25/00 Swartz et al. 6,095,418 8/1/00 Swartz et al. 6,095,421 8/1/00 Barkan et al. 6,101,483 8/8/00 Petrovich et al. 6,114,712 9/5/00 Dvorkis et al. 6,164,540 12/26/00 Bridgelall et al. 6,170,749B1 1/9/01 Goren et al. 6,209,788B1 4/3/01 Bridgelall et al. 6,220,514B1 4/24/01 Dvorkis et al. 6,264,106B1 7/24/01 Bridgelall et al. 6,330,973B1 12/18/01 Bridgelall et al. 6,334,573B1 1/1/02 Li et al. 6,360,949B1 3/26/02 Shepard et al. 6,3405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al.	KN	5,988,508	11/23/99	Bridgelall et al.					
6,095,418 8/1/00 Swartz et al. 6,095,421 8/1/00 Barkan et al. 6,101,483 8/8/00 Petrovich et al. 6,114,712 9/5/00 Dvorkis et al. 6,164,540 12/26/00 Bridgelall et al. 6,170,749B1 1/9/01 Goren et al. 6,209,78BB1 4/3/01 Bridgelall et al. 6,220,514B1 4/24/01 Dvorkis et al. 6,264,106B1 7/24/01 Bridgelall et al. 6,330,973B1 12/18/01 Bridgelall et al. 6,334,573B1 1/1/02 Li et al. 6,360,949B1 3/26/02 Shepard et al. 6,405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al.		6,029,893	2/29/00	Tan et al.					
6,095,421 8/1/00 Barkan et al. 6,101,483 8/8/00 Petrovich et al. 6,114,712 9/5/00 Dvorkis et al. 6,164,540 12/26/00 Bridgelall et al. 6,170,749B1 1/9/01 Goren et al. 6,209,788B1 4/3/01 Bridgelall et al. 6,220,514B1 4/24/01 Dvorkis et al. 6,264,106B1 7/24/01 Bridgelall et al. 6,330,973B1 12/18/01 Bridgelall et al. 6,334,573B1 1/1/02 Li et al. 6,360,949B1 3/26/02 Shepard et al. 6,382,513 B1 5/7/02 Dvorkis et al. 6,405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al.		6,092,725	7/25/00	Swartz et al.					
6,101,483 8/8/00 Petrovich et al. 6,114,712 9/5/00 Dvorkis et al. 6,164,540 12/26/00 Bridgelall et al. 6,170,749B1 1/9/01 Goren et al. 6,209,78BB1 4/3/01 Bridgelall et al. 6,220,514B1 4/24/01 Dvorkis et al. 6,264,106B1 7/24/01 Bridgelall et al. 6,330,973B1 12/18/01 Bridgelall et al. 6,334,573B1 1/1/02 Li et al. 6,360,949B1 3/26/02 Shepard et al. 6,360,949B1 3/26/02 Shepard et al. 6,382,513 B1 5/7/02 Dvorkis et al. 6,405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al.		6,095,418	8/1/00	Swartz et al.					
6,114,712 9/5/00 Dvorkis et al. 6,164,540 12/26/00 Bridgelall et al. 6,170,749B1 1/9/01 Goren et al. 6,209,78BB1 4/3/01 Bridgelall et al. 6,220,514B1 4/24/01 Dvorkis et al. 6,264,106B1 7/24/01 Bridgelall et al. 6,330,973B1 12/18/01 Bridgelall et al. 6,334,573B1 1/1/02 Li et al. 6,360,949B1 3/26/02 Shepard et al. 6,405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al.		6,095,421	8/1/00	Barkan et al.					
6,164,540 12/26/00 Bridgelall et al. 6,170,749B1 1/9/01 Goren et al. 6,209,78BB1 4/3/01 Bridgelall et al. 6,220,514B1 4/24/01 Dvorkis et al. 6,264,106B1 7/24/01 Bridgelall et al. 6,330,973B1 12/18/01 Bridgelall et al. 6,334,573B1 1/1/02 Li et al. 6,360,949B1 3/26/02 Shepard et al. 6,382,513 B1 5/7/02 Dvorkis et al. 6,405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al.		6,101,483	8/8/00	Petrovich et al.					
6,170,749B1 1/9/01 Goren et al. 6,209,788B1 4/3/01 Bridgelall et al. 6,220,514B1 4/24/01 Dvorkis et al. 6,264,106B1 7/24/01 Bridgelall et al. 6,330,973B1 12/18/01 Bridgelall et al. 6,334,573B1 1/1/02 Li et al. 6,360,949B1 3/26/02 Shepard et al. 6,382,513 B1 5/7/02 Dvorkis et al. 6,405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,410,931B1 6/25/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al.		6,114,712	9/5/00	Dvorkis et al.					
6,209,788B1 4/3/01 Bridgelall et al. 6,220,514B1 4/24/01 Dvorkis et al. 6,264,106B1 7/24/01 Bridgelall et al. 6,330,973B1 12/18/01 Bridgelall et al. 6,334,573B1 1/1/02 Li et al. 6,360,949B1 3/26/02 Shepard et al. 6,382,513 B1 5/7/02 Dvorkis et al. 6,405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al.		6,164,540	12/26/00	Bridgelall et al.					
6,220,514B1 4/24/01 Dvorkis et al. 6,264,106B1 7/24/01 Bridgelall et al. 6,330,973B1 12/18/01 Bridgelall et al. 6,334,573B1 1/1/02 Li et al. 6,360,949B1 3/26/02 Shepard et al. 6,382,513 B1 5/7/02 Dvorkis et al. 6,405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al.		6,170,749B1	1/9/01	Goren et al.					
6,264,106B1 7/24/01 Bridgelall et al. 6,330,973B1 12/18/01 Bridgelall et al. 6,334,573B1 1/1/02 Li et al. 6,360,949B1 3/26/02 Shepard et al. 6,382,513 B1 5/7/02 Dvorkis et al. 6,405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al.		6,209,788B1	4/3/01	Bridgelall et al.					
6,330,973B1 12/18/01 Bridgelall et al. 6,334,573B1 1/1/02 Li et al. 6,360,949B1 3/26/02 Shepard et al. 6,382,513 B1 5/7/02 Dvorkis et al. 6,405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al.		6,220,514B1	4/24/01	Dvorkis et al.					
6,334,573B1 1/1/02 Li et al. 6,360,949B1 3/26/02 Shepard et al. 6,382,513 B1 5/7/02 Dvorkis et al. 6,405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al.		6,264,106B1	7/24/01	Bridgelall et al.					
6,360,949B1 3/26/02 Shepard et al. 6,382,513 B1 5/7/02 Dvorkis et al. 6,405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al.		6,330,973B1	12/18/01	Bridgelall et al.					
6,382,513 B1 5/7/02 Dvorkis et al. 6,405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al. 2002/0085516A1 7/4/02 Bridgelall		6,334,573B1	1/1/02	Li et al.					
6,405,102B1 6/11/02 Swartz et al. 6,410,931B1 6/25/02 Dvorkis et al. 6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al. 2002/0085516A1 7/4/02 Bridgelall		6,360,949B1	3/26/02	Shepard et al.	,				
6,410,931B1 6/25/02 Dvorkis et al. 6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al. 2002/0085516A1 7/4/02 Bridgelall		6,382,513 B1	5/7/02	Dvorkis et al.					
6,412,697B1 7/2/02 Bridgelall et al. 6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al. 2002/0085516A1 7/4/02 Bridgelall		6,405,102B1	6/11/02	Swartz et al.					
6,415,982B2 7/9/02 Bridgelall et al. 2002/0060245A1 5/23/02 Dvorkis et al. 2002/0085516A1 7/4/02 Bridgelall		6,410,931B1	6/25/02	Dvorkis et al.					
2002/0060245A1 5/23/02 Dvorkis et al. 2002/0085516A1 7/4/02 Bridgelall		6,412,697B1	7/2/02	Bridgelall et al.					
2002/0085516A1 7/4/02 Bridgelall		6,415,982B2	7/9/02	Bridgelall et al.					
3.		2002/0060245A1	5/23/02	Dvorkis et al.					
2002/0126013A1 9/12/02 Bridgelall		2002/0085516A1	7/4/02	Bridgelall					
	KN	2002/0126013A1	9/12/02	Bridgelall					

OTHER DOCUMENTS

Examiner

Date Considered

Examiner: Initial if citation considered, whether or nor citation is in conformance with MPEP \$609; Draw line through

citation if not in conformance and not/considered. Include copy of this form with next communication to the applicant.

*